On Monday, Shares of QUALCOMM Incorporated (NASDAQ:QCOM), gained 0.73% to $67.36, as technology stocks were most higher in late afternoon trade Monday with shares of technology companies in the S&P 500 adding 0.7%.
QUALCOMM Incorporated designs, develops, manufactures, and markets digital communications products and services in China, South Korea, Taiwan, and the United States. The company operates through three segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Planned Initiatives (QSI).
Shares of Baxter International Inc. (NYSE:BAX), inclined 0.89% to $70.03, during its last trading session.
Baxter’s biopharmaceutical spin-off Baxalta will be a member of the S&P 500 when it starts trading July 1, replacing QEP Resources which will move to the S&P Midcap 400.
Baxter International Inc., develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions.
Finally, Abbott Laboratories (NYSE:ABT), ended its last trade with 0.28% gain, and closed at $50.03, hitting its highest level.
Mylan N.V., issued the following statement regarding Abbott Laboratories’ (ABT) declared intention to support Mylan’s offer to acquire Perrigo Company plc (NYSE: PRGO; TASE) and vote in favor of this acquisition at Mylan’s forthcoming shareholder meeting. Abbott is presently Mylan’s largest shareholder, owning 14.5% of Mylan’s outstanding shares, and is an important long-term stakeholder of Mylan through various manufacturing partnerships.
Mylan Executive Chairman Robert J. Coury stated: “We are very happy that, while Abbott is under no obligation to do so, Abbott has voluntarily chosen to express its support of Mylan, our planned growth plan and stand-alone strategy, and our projected combination with Perrigo. When we attained Abbott’s non-U.S. developed markets specialty and branded generics business earlier this year, we gained an important stakeholder in Abbott, which understands the powerful potential of our platform, and the critical importance of our scale and breadth across our distribution channels. We are grateful for Abbott’s support of our long-term vision, which we firmly believe will continue to deliver strong near-term and long-term returns in this rapidly evolving industry and will promote the sustainable success of Mylan’s business.”
Abbott Laboratories manufactures and sells health care products worldwide. Its Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome; intrahepatic cholestasis or depressive symptoms; gynecological disorders; dyslipidemia; hypertension; hypothyroidism; pain, fever, and inflammation; hormone replacement therapy; anti-infective and influenza vaccines; and product that regulates physiological rhythm of the colon.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
